Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 7/20 | 0.65 |
| ▸ | BRD4 | O60885 | 3/20 | 0.65 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.65 |
| ▸ | TTK | P33981 | 4/20 | 0.59 |
| ▸ | AURKA | O14965 | 2/20 | 0.59 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.59 |
| ▸ | CDK2 | P24941 | 1/20 | 0.59 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.58 |
| ▸ | CDK4 | P11802 | 1/20 | 0.58 |
| ▸ | CCND3 | P30281 | 1/20 | 0.58 |
| ▸ | CDK9 | P50750 | 1/20 | 0.58 |
| ▸ | PRKDC | P78527 | 4/20 | 0.58 |
| ▸ | CSF1R | P07333 | 2/20 | 0.58 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.57 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.56 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.56 |
| ▸ | IGF1R | P08069 | 5/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1780690 | 0.95 | PLK1 (0.60) | PLK1BRD4BRDTTTKAURKA | |
| SCHEMBL1782206 | 0.95 | PLK1 (0.59) | PLK1BRD4BRDTTTKAURKA | |
| SCHEMBL1783737 | 0.89 | TTK (0.60) | PLK1BRD4BRDTTTKAURKA | |
| SCHEMBL1781475 | 0.88 | TTK (0.64) | PLK1BRD4BRDTTTKAURKA | |
| SCHEMBL1780549 | 0.88 | TTK (0.59) | PLK1BRD4BRDTTTKAURKA | |
| SCHEMBL1781682 | 0.87 | TTK (0.59) | PLK1BRD4BRDTTTKAURKA | |
| SCHEMBL1782949 | 0.87 | TTK (0.66) | PLK1BRD4BRDTTTKAURKA | |
| SCHEMBL1782244 | 0.86 | TTK (0.65) | TTKAURKACCNA2CDK2CDK4 | |
| SCHEMBL1782435 | 0.85 | TTK (0.58) | PLK1BRD4BRDTTTKAURKA | |
| SCHEMBL1781289 | 0.85 | TTK (0.68) | PLK1BRD4BRDTTTKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118238-A1 | 2-ANILINOPURIN-8-ONES AS INHIBITORS OF TTK/MPS1 FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | BUB1, BUB1B, TTBK1 | PLK1 7/4885BRD4 3407/4885BRDT 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.